Diamond & Jewellery · Founded 1986 · www.goldiam.com · BSE 526729 · NSE GOLDIAM INT. · ISIN INE025B01025
No Notes Added Yet
Business
Goldiam International Ltd. is an India-based integrated manufacturer and exporter of studded diamond jewellery. The company's core business involves designing, manufacturing, and marketing high-quality diamond jewellery to retailers, wholesalers, and e-commerce players primarily in the USA, Europe, and India. Goldiam operates on a B2B model, leveraging its manufacturing capabilities and design expertise to fulfill orders for its global clientele. The company also has a presence in the lab-grown diamond (LGD) segment, engaging in the manufacturing of LGDs and LGD jewellery. It makes money by selling these finished jewellery products and loose lab-grown diamonds to its B2B customers.
Revenue Mix
Goldiam International's revenue primarily comes from two main segments:
Diamond Jewellery Manufacturing: This involves the design and production of studded natural diamond jewellery for export and domestic markets. This has historically been the company's mainstay.
Lab-Grown Diamonds & Jewellery: The company has increasingly diversified into the manufacturing of lab-grown diamonds (both loose stones and set in jewellery), capitalizing on the growing demand for sustainable and ethically sourced alternatives. This segment has been a significant growth driver in recent years.
While specific percentage breakdowns fluctuate and are not always explicitly delineated for public consumption in simple terms, the company's strategic focus indicates a significant and growing contribution from the lab-grown diamonds and jewellery segment alongside its traditional natural diamond jewellery business.
Industry
The global diamond and jewellery industry is characterized by its fragmented nature, with a few large integrated players and numerous small to medium-sized manufacturers and retailers. India is a global hub for diamond cutting and polishing, and a significant manufacturing base for diamond jewellery. Goldiam positions itself as a quality-focused, integrated manufacturer with strong export capabilities, particularly to the US market. The company competes with other Indian jewellery exporters and global jewellery manufacturers. Its pivot towards lab-grown diamonds positions it in a rapidly expanding niche, differentiating it from traditional players who exclusively deal in natural diamonds.
MOAT
Goldiam's competitive advantages include:
Integrated Manufacturing: Control over the entire manufacturing process, from design to finished product, allows for efficiency, cost control, and quality assurance.
Established Export Network: Long-standing relationships and a robust distribution network, particularly with key retailers and e-commerce platforms in the US, provide consistent order flow.
Agility & Diversification: Early and strategic entry into the lab-grown diamond segment demonstrates adaptability to changing consumer preferences and market trends, providing a diversified revenue stream and capturing new market share.
Design & Manufacturing Expertise: Decades of experience in jewellery manufacturing, enabling them to meet diverse design requirements and quality standards of international clients.
Growth Drivers
Growing Demand for Lab-Grown Diamonds (LGDs): Increasing consumer preference for ethically sourced, environmentally friendly, and more affordable LGDs is a significant tailwind for Goldiam's LGD segment.
E-commerce Penetration: Expansion of online jewellery retail globally, particularly in key export markets, creates new sales channels and demand for manufactured jewellery.
Increased Discretionary Spending: Rising disposable incomes in key markets, including India, can drive demand for luxury and lifestyle products like diamond jewellery.
Market Share Gains in LGDs: Goldiam's focus on scaling its LGD manufacturing and B2B supply chain positions it to capture a larger share of this growing market.
Product Innovation & Design: Continuous introduction of new designs and collections catering to evolving fashion trends can sustain customer interest and drive sales.
Risks
Raw Material Price Volatility: Fluctuations in the prices of natural diamonds, gold, and other precious metals can impact manufacturing costs and margins.
Economic Downturns: As a luxury item, demand for diamond jewellery is sensitive to global and regional economic slowdowns, affecting consumer spending.
Changing Consumer Preferences: Shifts in fashion trends or evolving perceptions around natural vs. lab-grown diamonds could impact demand for specific product categories.
Intense Competition: The industry is highly competitive, both from traditional natural diamond players and new entrants in the lab-grown segment, leading to potential margin pressure.
Regulatory & Trade Policies: Changes in trade tariffs, import/export regulations, and ethical sourcing standards in key markets can affect operations and profitability.
Currency Fluctuations: As a significant exporter, adverse movements in foreign exchange rates (e.g., INR vs. USD) can impact revenue realization and profitability.
Management & Ownership
Goldiam International Ltd. is primarily promoter-driven, with the Kothari family being the key promoters and holding a significant stake in the company. Mr. Manan Shah (MD) and Mr. Rashesh Kothari (Chairman & Jt. MD) lead the management. The company benefits from the long-standing experience of its promoters in the diamond and jewellery industry. The ownership structure reflects a strong promoter holding, indicating alignment of interests with the company's long-term growth.
Outlook
Goldiam International Ltd. is well-positioned to capitalize on the evolving dynamics of the global diamond and jewellery market. The strategic shift and strong capabilities in the rapidly expanding lab-grown diamond segment provide a significant growth runway, complementing its established natural diamond jewellery export business. The company's integrated manufacturing and strong relationships with international retailers offer a stable foundation. However, the business remains susceptible to macro-economic headwinds impacting discretionary spending, raw material price volatility, and intense competition, which could put pressure on margins. Continued successful execution in the lab-grown segment and effective management of traditional business challenges will be crucial for sustained performance.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
| #(Fig in Cr.) | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 148 | 166 | 137 | 280 | 199 | 230 | 193 | 320 | 235 | 326 |
| Other Income | 3 | 4 | 4 | 8 | 3 | 6 | 9 | 20 | 9 | 38 |
| Total Income | 151 | 170 | 141 | 288 | 202 | 236 | 202 | 340 | 243 | 364 |
| Total Expenditure | 124 | 136 | 106 | 217 | 159 | 189 | 154 | 249 | 185 | 260 |
| Operating Profit | 27 | 34 | 35 | 71 | 43 | 47 | 47 | 91 | 58 | 104 |
| Interest | -0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 2 |
| Depreciation | 2 | 1 | 2 | 2 | 4 | 2 | 2 | 2 | 6 | 5 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 26 | 33 | 33 | 69 | 38 | 45 | 46 | 89 | 51 | 97 |
| Provision for Tax | 8 | 11 | 11 | 19 | 14 | 12 | 14 | 20 | 14 | 23 |
| Profit After Tax | 18 | 22 | 22 | 50 | 23 | 34 | 31 | 68 | 37 | 74 |
| Adjustments | 0 | 0 | -0 | 0 | -0 | 0 | 0 | -0 | -0 | -0 |
| Profit After Adjustments | 18 | 22 | 22 | 50 | 23 | 34 | 31 | 68 | 37 | 74 |
| Adjusted Earnings Per Share | 1.2 | 1.5 | 1.6 | 3.5 | 1.6 | 2.4 | 2.1 | 4.5 | 2.5 | 4.9 |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 330 | 315 | 319 | 446 | 365 | 406 | 688 | 533 | 603 | 781 | 977 | 1074 |
| Other Income | 15 | 8 | 12 | 18 | 22 | 7 | 25 | 21 | 14 | 20 | 44 | 76 |
| Total Income | 345 | 323 | 330 | 464 | 387 | 413 | 712 | 554 | 617 | 801 | 1021 | 1149 |
| Total Expenditure | 298 | 287 | 293 | 391 | 320 | 328 | 558 | 429 | 488 | 618 | 772 | 848 |
| Operating Profit | 47 | 36 | 37 | 74 | 66 | 86 | 155 | 125 | 128 | 183 | 249 | 300 |
| Interest | 2 | 3 | 2 | 3 | 2 | 1 | 1 | 0 | 0 | 1 | 4 | 3 |
| Depreciation | 3 | 3 | 3 | 3 | 2 | 4 | 5 | 7 | 6 | 9 | 15 | 15 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 16 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 42 | 31 | 33 | 68 | 62 | 97 | 149 | 117 | 122 | 173 | 231 | 283 |
| Provision for Tax | 9 | 11 | 13 | 22 | 17 | 30 | 43 | 32 | 31 | 55 | 60 | 71 |
| Profit After Tax | 33 | 21 | 20 | 46 | 45 | 67 | 106 | 85 | 91 | 117 | 171 | 210 |
| Adjustments | -1 | 15 | 8 | 9 | 10 | 6 | 15 | 4 | 6 | 12 | 20 | 0 |
| Profit After Adjustments | 32 | 35 | 28 | 55 | 55 | 73 | 121 | 90 | 97 | 129 | 190 | 210 |
| Adjusted Earnings Per Share | 2 | 2.1 | 1.7 | 3.6 | 3.7 | 5 | 8.3 | 6.2 | 6.8 | 9 | 12.7 | 14 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 25% | 22% | 19% | 11% |
| Operating Profit CAGR | 36% | 26% | 24% | 18% |
| PAT CAGR | 46% | 26% | 21% | 18% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 8% | 49% | 17% | 40% |
| ROE Average | 18% | 17% | 17% | 14% |
| ROCE Average | 25% | 23% | 24% | 19% |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 281 | 330 | 356 | 384 | 410 | 465 | 520 | 586 | 630 | 740 | 1106 |
| Minority's Interest | 14 | 13 | 12 | 8 | 5 | 16 | 6 | 6 | 5 | 5 | 5 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 1 | -2 | -2 | -2 | -2 | 2 | 5 | 4 | 5 | 21 | 40 |
| Total Current Liabilities | 126 | 105 | 116 | 85 | 89 | 130 | 101 | 106 | 92 | 127 | 210 |
| Total Liabilities | 422 | 447 | 482 | 475 | 502 | 614 | 632 | 702 | 733 | 893 | 1361 |
| Fixed Assets | 23 | 22 | 21 | 21 | 20 | 41 | 40 | 43 | 45 | 60 | 93 |
| Other Non-Current Assets | 39 | 44 | 28 | 51 | 53 | 44 | 27 | 23 | 12 | 7 | 22 |
| Total Current Assets | 359 | 381 | 433 | 403 | 429 | 529 | 565 | 636 | 676 | 826 | 1247 |
| Total Assets | 422 | 447 | 482 | 475 | 502 | 614 | 632 | 702 | 733 | 893 | 1361 |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 21 | 43 | 13 | 29 | 64 | 55 | 92 | 87 | 119 | 145 | 182 |
| Cash Flow from Operating Activities | 59 | 13 | -15 | 86 | 67 | 49 | -10 | 65 | 107 | -10 | 24 |
| Cash Flow from Investing Activities | 9 | -16 | 27 | -11 | -24 | -12 | 95 | -2 | -28 | 63 | -71 |
| Cash Flow from Financing Activities | -45 | -27 | 4 | -41 | -52 | -0 | -90 | -31 | -54 | -16 | 171 |
| Net Cash Inflow / Outflow | 22 | -30 | 16 | 34 | -9 | 37 | -5 | 32 | 26 | 37 | 124 |
| Closing Cash & Cash Equivalent | 43 | 13 | 29 | 64 | 55 | 92 | 87 | 119 | 145 | 182 | 306 |
| # | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 1.95 | 2.12 | 1.7 | 3.62 | 3.75 | 4.97 | 8.35 | 6.17 | 6.8 | 9.05 | 12.65 |
| CEPS(Rs) | 2.15 | 1.4 | 1.38 | 3.21 | 3.23 | 4.78 | 7.66 | 6.37 | 6.81 | 8.86 | 12.3 |
| DPS(Rs) | 0.37 | 0.3 | 0.22 | 0.45 | 0.97 | 1.2 | 0.9 | 1.5 | 0.9 | 2.26 | 2.07 |
| Book NAV/Share(Rs) | 16.88 | 19.85 | 21.42 | 25.08 | 27.74 | 31.44 | 35.78 | 40.31 | 44.28 | 51.97 | 73.46 |
| Core EBITDA Margin(%) | 9.58 | 8.88 | 8.02 | 12.52 | 12.16 | 19.29 | 18.93 | 19.51 | 18.99 | 20.88 | 20.95 |
| EBIT Margin(%) | 13.39 | 10.72 | 10.96 | 15.87 | 17.53 | 24.07 | 21.73 | 22.11 | 20.28 | 22.25 | 24 |
| Pre Tax Margin(%) | 12.67 | 9.9 | 10.31 | 15.23 | 16.99 | 23.94 | 21.61 | 22.03 | 20.25 | 22.09 | 23.63 |
| PAT Margin (%) | 10 | 6.56 | 6.38 | 10.41 | 12.4 | 16.53 | 15.41 | 15.98 | 15.08 | 14.99 | 17.46 |
| Cash Profit Margin (%) | 10.81 | 7.38 | 7.18 | 11.01 | 13.08 | 17.42 | 16.19 | 17.36 | 16.09 | 16.16 | 18.95 |
| ROA(%) | 7.73 | 4.76 | 4.38 | 9.71 | 9.25 | 12.03 | 17.01 | 12.77 | 12.67 | 14.4 | 15.13 |
| ROE(%) | 12.3 | 6.77 | 5.93 | 12.55 | 11.38 | 15.34 | 21.52 | 15.41 | 14.95 | 17.09 | 18.48 |
| ROCE(%) | 13.26 | 9.79 | 9.26 | 17.64 | 15.44 | 21.6 | 29.6 | 21.27 | 20.11 | 25.2 | 24.85 |
| Receivable days | 139.98 | 122.61 | 117.45 | 79.49 | 92.24 | 102.83 | 81.7 | 111.6 | 87.79 | 68.42 | 60.59 |
| Inventory Days | 119.5 | 136.6 | 155.99 | 100.07 | 99.88 | 90.2 | 75.39 | 145.54 | 142.55 | 142.79 | 181.51 |
| Payable days | 102.65 | 106.43 | 105.29 | 66.36 | 79.48 | 110.52 | 60.29 | 81.8 | 68.96 | 49.27 | 51.08 |
| PER(x) | 3.3 | 6.09 | 5.26 | 3.05 | 3.54 | 10.29 | 13.59 | 15.6 | 18.83 | 31.19 | 15.9 |
| Price/Book(x) | 0.38 | 0.65 | 0.42 | 0.44 | 0.48 | 1.63 | 3.17 | 2.39 | 2.89 | 5.43 | 2.74 |
| Dividend Yield(%) | 5.81 | 2.32 | 2.52 | 4.09 | 7.35 | 2.35 | 0.79 | 1.56 | 0.7 | 0.8 | 1.03 |
| EV/Net Sales(x) | 0.34 | 0.74 | 0.49 | 0.29 | 0.41 | 1.69 | 2.27 | 2.4 | 2.78 | 4.92 | 2.82 |
| EV/Core EBITDA(x) | 2.39 | 6.4 | 4.17 | 1.78 | 2.24 | 8.03 | 10.1 | 10.21 | 13.07 | 21.03 | 11.07 |
| Net Sales Growth(%) | 2.63 | -4.57 | 1.16 | 40.1 | -18.34 | 11.38 | 69.39 | -22.47 | 13.07 | 29.54 | 25.08 |
| EBIT Growth(%) | 40.24 | -23.64 | 3.46 | 102.87 | -9.82 | 52.97 | 52.93 | -21.14 | 3.73 | 42.12 | 34.92 |
| PAT Growth(%) | 51.09 | -37.37 | -1.63 | 128.39 | -2.69 | 48.47 | 57.9 | -19.6 | 6.71 | 28.82 | 45.68 |
| EPS Growth(%) | 52.93 | 8.6 | -20.08 | 113.16 | 3.7 | 32.51 | 68.03 | -26.12 | 10.24 | 33.09 | 39.83 |
| Debt/Equity(x) | 0.17 | 0.09 | 0.1 | 0.07 | 0.02 | 0.05 | 0.01 | 0 | 0 | 0.01 | 0.03 |
| Current Ratio(x) | 2.84 | 3.63 | 3.74 | 4.75 | 4.81 | 4.06 | 5.57 | 6 | 7.32 | 6.49 | 5.94 |
| Quick Ratio(x) | 2.03 | 2.35 | 2.54 | 3.5 | 3.76 | 3.24 | 3.83 | 3.66 | 4.91 | 3.44 | 3.16 |
| Interest Cover(x) | 18.54 | 13.16 | 16.96 | 24.73 | 32.47 | 186.93 | 181.11 | 298.76 | 764.09 | 140.97 | 65.21 |
| Total Debt/Mcap(x) | 0.44 | 0.14 | 0.25 | 0.15 | 0.04 | 0.03 | 0 | 0 | 0 | 0 | 0.01 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 64.26 | 64.26 | 63.32 | 62.38 | 62.06 | 61.87 | 58.51 | 58.51 | 58.51 | 58.51 |
| FII | 0.07 | 0.16 | 0.57 | 0.75 | 1.35 | 0.88 | 1.47 | 0.74 | 0.62 | 1.99 |
| DII | 0 | 0 | 0 | 0.36 | 0.68 | 0.91 | 1.14 | 1.1 | 0.95 | 0.78 |
| Public | 35.67 | 35.59 | 36.11 | 36.52 | 35.92 | 36.34 | 38.88 | 39.65 | 39.91 | 38.71 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 6.86 | 6.86 | 6.76 | 6.66 | 6.63 | 6.61 | 6.61 | 6.61 | 6.61 | 6.61 |
| FII | 0.01 | 0.02 | 0.06 | 0.08 | 0.14 | 0.09 | 0.17 | 0.08 | 0.07 | 0.22 |
| DII | 0 | 0 | 0 | 0.04 | 0.07 | 0.1 | 0.13 | 0.12 | 0.11 | 0.09 |
| Public | 3.81 | 3.8 | 3.86 | 3.9 | 3.84 | 3.88 | 4.39 | 4.48 | 4.51 | 4.37 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10.68 | 10.68 | 10.68 | 10.68 | 10.68 | 10.68 | 11.29 | 11.29 | 11.29 | 11.29 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +25% | +22% | +19% | +11% |
| Operating Profit CAGR | +36% | +26% | +24% | +18% |
| PAT CAGR | +46% | +26% | +21% | +18% |
| Share Price CAGR | +8% | +49% | +17% | +40% |
| ROE Average | +18% | +17% | +17% | +14% |
| ROCE Average | +25% | +23% | +24% | +19% |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 64.26 | 64.26 | 63.32 | 62.38 | 62.06 | 61.87 | 58.51 | 58.51 | 58.51 | 58.51 |
| FII | 0.07 | 0.16 | 0.57 | 0.75 | 1.35 | 0.88 | 1.47 | 0.74 | 0.62 | 1.99 |
| DII | 0 | 0 | 0 | 0.36 | 0.68 | 0.91 | 1.14 | 1.1 | 0.95 | 0.78 |
| Public | 35.67 | 35.59 | 36.11 | 36.52 | 35.92 | 36.34 | 38.88 | 39.65 | 39.91 | 38.71 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 6.86 | 6.86 | 6.76 | 6.66 | 6.63 | 6.61 | 6.61 | 6.61 | 6.61 | 6.61 |
| FII | 0.01 | 0.02 | 0.06 | 0.08 | 0.14 | 0.09 | 0.17 | 0.08 | 0.07 | 0.22 |
| DII | 0 | 0 | 0 | 0.04 | 0.07 | 0.1 | 0.13 | 0.12 | 0.11 | 0.09 |
| Public | 3.81 | 3.8 | 3.86 | 3.9 | 3.84 | 3.88 | 4.39 | 4.48 | 4.51 | 4.37 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10.68 | 10.68 | 10.68 | 10.68 | 10.68 | 10.68 | 11.29 | 11.29 | 11.29 | 11.29 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
Your relationship manager will connect with you shortly.